REG - Destiny Pharma PLC - Board Changes

Destiny PharmaAnnouncement

26/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220526:nRSZ8331Ma&default-theme=true

RNS Number : 8331M  Destiny Pharma PLC  26 May 2022

Destiny Pharma plc

 

("Destiny Pharma" or "the Company")

 

Destiny Pharma appoints three Non-Executive Directors

 

Brighton, United Kingdom - 26 May 2022 - Destiny Pharma plc (AIM:DEST), a
clinical stage innovative biotechnology company focused on the development of
novel medicines that can prevent life-threatening infections, today announces
the appointments of James Stearns, Aled Williams and Nigel Brooksby as
Non-Executive Directors with effect from 1 June 2022. James Stearns is
replacing Dr Huaizheng Peng. The Company has been looking to add Non-Executive
Directors following the retirement of Peter Morgan in March this year and has
decided to add Aled and Nigel as two new appointments. The Board has expanded
its skills and experience base through these additions and is well positioned
to continue to deliver its strategy.

 

James Stearns is the Chief Investment Officer (Europe and America) of China
Medical System Holdings Limited (CMS), focusing on its M&A driven growth
strategy and overseeing the Venture Programme.  James brings considerable
experience in the financial markets having previously worked for both the
sellside (Director, Corporate Broking and Advisory at Panmure Gordon) and
buyside (Investment Director at LivingBridge). James holds a Joint Honours
degree from the University of Bristol in Economics and Accounting.

 

Aled Williams is Chief Executive Officer of Enthera Pharmaceuticals Srl and
was recently Chief Business Officer of Polyneuron Pharmaceuticals Ag. Aled has
over 25 years of leadership experience in the pharmaceutical industry, holding
senior positions in large pharmaceutical companies (AstraZeneca, Pfizer,
Novartis and Bristol-Myers Squibb) and multiple executive management roles in
smaller biotech companies. Aled has spent much of his career with
responsibility for the external interface from a company, portfolio and asset
perspective across a range of different disease areas, including
anti-infectives. A microbiologist by training, prior to joining the pharma
& biotech industry Aled spent a number of years working in public health.

 

Nigel Brooksby has extensive experience in the life science sector and has
been involved as Chair/ Director/ Strategic Adviser in several fund raisings,
including advising Akari Therapeutics on its 2015 NASDAQ listing. Nigel has
also undertaken many projects assisting biotech companies in their partnering
arrangements with major pharmaceutical companies and has previously held
senior global roles at Sanofi, Wellcome (now GSK) and Pfizer.  Until his
retirement in 2010, Nigel was a Member of the Sanofi Executive Committee in
Europe and North America, and Chair and Managing Director of the Sanofi Group
in the UK and Ireland. He has worked internationally based in Europe, the USA,
Latin America, the Middle East and Africa.

 

Nick Rodgers, Chair of the Board of Directors, Destiny Pharma, said: "We are
delighted to announce these high calibre appointments to the Destiny Board.
The skillset that these individuals bring to the table will be invaluable as
we continue to drive forward our strategy and execute our Phase 3 clinical
development plans moving towards our next phase of growth. This is an exciting
time for Destiny, excellent progress was achieved in the last year developing
the clinical pipeline and the Company is well positioned for the future."

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com (about%3Ablank)

 

Optimum Strategic Communications  (about%3Ablank)

Mary Clark / Manel Mateus /Vici Rabbetts

+44 (0) 208 078 4357

DestinyPharma@optimumcomms.com (about%3Ablank)

 

finnCap Ltd (Nominated Advisor and Broker)

Geoff Nash / Kate Bannatyne / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

 

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has recently completed a positive Phase 2b clinical trial targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA.
It is also co-developing SporCov, a novel, biotherapeutic product for the
prevention of COVID-19 and other viral respiratory infections and has earlier
grant funded XF research projects.

For further information on the company, please visit www.destinypharma.com

Forward looking statements

Certain information contained in this announcement, including any information
as to the Group's strategy, plans or future financial or operating
performance, constitutes "forward-looking statements". These forward-looking
statements may be identified by the use of forward-looking terminology,
including the terms "believes", "estimates", "anticipates", "projects",
"expects", "intends", "aims", "plans", "predicts", "may", "will", "seeks"
"could" "targets" "assumes" "positioned" or "should" or, in each case, their
negative or other variations or comparable terminology, or by discussions of
strategy, plans, objectives, goals, future events or intentions. These
forward-looking statements include all matters that are not historical facts.
They appear in a number of places throughout this announcement and include
statements regarding the intentions, beliefs or current expectations of the
Directors concerning, among other things, the Group's results of operations,
financial condition, prospects, growth, strategies and the industries in which
the Group operates. The directors of the company believe that the expectations
reflected in these statements are reasonable but may be affected by a number
of variables which could cause actual results or trends to differ materially.
Each forward-looking statement speaks only as of the date of the particular
statement. By their nature, forward-looking statements involve risks and
uncertainties because they relate to events and depend on circumstances that
may or may not occur in the future or are beyond the Group's control. Forward
looking statements are not guarantees of future performance. Even if the
Group's actual results of operations, financial condition and the development
of the industries in which the Group operates are consistent with the
forward-looking statements contained in this document, those results or
developments may not be indicative of results or developments in subsequent
periods.

 

The following information is disclosed pursuant to Schedule Two paragraph (g)
of the AIM Rules for Companies.

 

Nigel Stanley Brooksby, aged 71, has been a director of the following
companies during the five years preceding the date of this announcement:

 

 Current                                Past

 International Society of Hypertension  Novacta Biosystems Limited*
 Steel Bars Limited                     Chronos Therapeutics Limited
 Steel Bars Search Limited              Prism Ideas Limited
                                        Clinical Insights Limited
                                        Unicorn Pharma Services Limited
                                        Porton Biopharma Limited
                                        Neurocentrx Pharma Limited
                                        IOSBIO Ltd
                                        Pertinax Pharma Limited

 

*Nigel Brooksby was a director at Novacta Biosystems Limited when the Company
was dissolved by Members Voluntary Liquidation in April 2019.

 

Aled Paton Williams, aged 52, has been a director of the following companies
during the five years preceding the date of this announcement:

 

 Current                  Past

 Enthera Pharmaceuticals  Polyneuron Pharmaceutics AG
                          VectivBio Pharmaceuticals
                          Therachon Pharmaceuticals

 

James Patrick Stearns, aged 42, has been a director of the following companies
during the five years preceding the date of this announcement:

 

 Current               Past

 Monkey Puzzle
 Howe Farming Limited
 Oakridge Farms

 

Aled Paton Williams, aged 52, has been a director of the following companies
during the five years preceding the date of this announcement:

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUVUNRUBUVUAR